Fresh Tracks Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Investments
  • 1

  • Share Price
  • $0.94
  • (As of Friday Closing)

Fresh Tracks Therapeutics General Information

Description

Fresh Tracks Therapeutics Inc does not have any operations as it has discontinued its activities.

Contact Information

Website
www.frtx.com
Formerly Known As
Brickell Biotech, Inc.
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2000 Central Avenue
  • Suite 100
  • Boulder, CO 80301
  • United States
+1 (720)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences
Former Stock Listing
FRTX
Corporate Office
  • 2000 Central Avenue
  • Suite 100
  • Boulder, CO 80301
  • United States
+1 (720)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fresh Tracks Therapeutics Stock Performance

As of 28-Feb-2025, Fresh Tracks Therapeutics’s stock price is $0.94. Its current market cap is $5.59M with 5.97M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.94 $0.94 $0.03 - $1.03 $5.59M 5.97M 2.76K -$1.06

Fresh Tracks Therapeutics Financials Summary

As of 31-Dec-2023, Fresh Tracks Therapeutics has a trailing 12-month revenue of $8.01M.

In Thousands,
USD 		TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (6,769) (6,769) (6,712) 5,025
Revenue 8,006 8,006 6,943 404
EBITDA (5,648) (5,648) (21,063) (39,383)
Net Income (5,694) (5,694) (21,102) (39,474)
Total Assets 11,586 11,586 10,271 29,717
Total Debt 0 0 49 69
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Fresh Tracks Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fresh Tracks Therapeutics‘s full profile, request access.

Request a free trial

Fresh Tracks Therapeutics Patents

  • 419

    Total Documents Applications and Grants

  • Total Patents Families

  • 117

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Fresh Tracks Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4522153-A1 Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor Pending 13-May-2022
JP-2020189856-A Crystalline form of sofpironium bromide and preparation method thereof Active 23-May-2019
JP-2020189839-A Crystalline form of sofpironium bromide and preparation method thereof Active 23-May-2019
AU-2020277881-A1 Crystalline form of sofpironium bromide and preparation method thereof Active 23-May-2019
CA-3139948-A1 Crystalline form of sofpironium bromide and preparation method thereof Pending 23-May-2019 C07D207/12
To view Fresh Tracks Therapeutics’s complete patent history, request access »

Fresh Tracks Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fresh Tracks Therapeutics Acquisitions (1)

Fresh Tracks Therapeutics’s most recent deal was a Merger/Acquisition with Vical. The deal was made on 03-Sep-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vical 03-Sep-2019 Merger/Acquisition Pharmaceuticals
To view Fresh Tracks Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Fresh Tracks Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Fresh Tracks Therapeutics’s complete esg history, request access »

Fresh Tracks Therapeutics FAQs

  • When was Fresh Tracks Therapeutics founded?

    Fresh Tracks Therapeutics was founded in 2009.

  • Where is Fresh Tracks Therapeutics headquartered?

    Fresh Tracks Therapeutics is headquartered in Boulder, CO.

  • What is the size of Fresh Tracks Therapeutics?

    Fresh Tracks Therapeutics has 4 total employees.

  • What industry is Fresh Tracks Therapeutics in?

    Fresh Tracks Therapeutics’s primary industry is Drug Delivery.

  • Is Fresh Tracks Therapeutics a private or public company?

    Fresh Tracks Therapeutics is a Public company.

  • What is the current stock price of Fresh Tracks Therapeutics?

    As of 28-Feb-2025 the stock price of Fresh Tracks Therapeutics is $0.94.

  • What is the current market cap of Fresh Tracks Therapeutics?

    The current market capitalization of Fresh Tracks Therapeutics is $5.59M.

  • What is Fresh Tracks Therapeutics’s current revenue?

    The trailing twelve month revenue for Fresh Tracks Therapeutics is $8.01M.

  • What is Fresh Tracks Therapeutics’s annual earnings per share (EPS)?

    Fresh Tracks Therapeutics’s EPS for 12 months was -$1.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »